MEDI 367 |
| As part of our program for applying nanotechnology to biomedicine we have focused on the design and preparation of multivalent nanoparticles. Our strategy involves a modular-convergent approach in which we develop terminally functionalized nanoparticle binding groups and separately prepare, using structure-based drug design, derivatives of ligands that bind to specific cellular markers. In this project, we selected tyrosine kinase inhibitors (TKI) of the anilinoquinazoline family as our targeting molecules onto which we would append a substituent that would interact with the nanoparticle binding moiety. In this presentation we will describe the synthesis of each module, the ligation using “click” chemistry and our preliminary efforts toward labeling the nanoparticles. |
|
Poster Session
7:00 PM-9:00 PM, Wednesday, August 22, 2007 BCEC -- Exhibit Hall - B2, Poster
Sci-Mix
Division of Medicinal Chemistry |